LUPIN has informed that it enclosed a Press release regarding launch of Rufinamide Oral Suspension, 40 mg/mL to market a generic equivalent of Banzel Oral Suspension, 40 mg/mL of Eisai Inc. This is disclosure pursuant to Regulation 30 of the Listing Regulations.
The above information is a part of company’s filings submitted to BSE.